ID   KSR1_HUMAN              Reviewed;         923 AA.
AC   Q8IVT5; F8WEA9; H7BYU0; Q13476;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   03-SEP-2014, sequence version 3.
DT   12-OCT-2022, entry version 179.
DE   RecName: Full=Kinase suppressor of Ras 1;
DE            EC=2.7.11.1 {ECO:0000250|UniProtKB:Q61097};
GN   Name=KSR1; Synonyms=KSR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-628 (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 243-899 (ISOFORM 2).
RX   PubMed=8521512; DOI=10.1016/0092-8674(95)90204-x;
RA   Therrien M., Chang H.C., Solomon N.M., Karim F.D., Wassarman D.A.,
RA   Rubin G.M.;
RT   "KSR, a novel protein kinase required for RAS signal transduction.";
RL   Cell 83:879-888(1995).
RN   [4]
RP   INTERACTION WITH MAP2K1; MAP2K2; HSP90AA1; 14-3-3 AND CDC37, SUBCELLULAR
RP   LOCATION, AND DOMAIN.
RX   PubMed=10409742; DOI=10.1128/mcb.19.8.5523;
RA   Stewart S., Sundaram M., Zhang Y., Lee J., Han M., Guan K.L.;
RT   "Kinase suppressor of Ras forms a multiprotein signaling complex and
RT   modulates MEK localization.";
RL   Mol. Cell. Biol. 19:5523-5534(1999).
RN   [5]
RP   REVIEW.
RX   PubMed=12007434; DOI=10.1016/s0960-9822(02)00831-x;
RA   Roy F., Therrien M.;
RT   "MAP kinase module: the Ksr connection.";
RL   Curr. Biol. 12:R325-R327(2002).
RN   [6]
RP   INTERACTION WITH MARK3.
RX   PubMed=12941695; DOI=10.1093/emboj/cdg426;
RA   Mueller J., Ritt D.A., Copeland T.D., Morrison D.K.;
RT   "Functional analysis of C-TAK1 substrate binding and identification of PKP2
RT   as a new C-TAK1 substrate.";
RL   EMBO J. 22:4431-4442(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-311, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-270 AND SER-334, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-270, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-270; THR-274; SER-334;
RP   SER-406 AND SER-569, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-406, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH VRK2.
RX   PubMed=20679487; DOI=10.1128/mcb.01581-09;
RA   Fernandez I.F., Blanco S., Lozano J., Lazo P.A.;
RT   "VRK2 inhibits mitogen-activated protein kinase signaling and inversely
RT   correlates with ErbB2 in human breast cancer.";
RL   Mol. Cell. Biol. 30:4687-4697(2010).
RN   [14]
RP   INTERACTION WITH AKAP13 AND BRAF, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21102438; DOI=10.1038/ncb2130;
RA   Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K.,
RA   Davis R.J., Scott J.D.;
RT   "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade.";
RL   Nat. Cell Biol. 12:1242-1249(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-311, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-270; THR-274; SER-311;
RP   SER-334; SER-351; SER-406; THR-425 AND SER-569, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18] {ECO:0007744|PDB:5VYK}
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 27-172, FUNCTION, SUBUNIT,
RP   INTERACTION WITH BRAF; MAP2K1; MAP2K2; HSP90AA1; 14-3-3 AND CDC37, DOMAIN,
RP   AND MUTAGENESIS OF LEU-47; CYS-62; GLU-72; 602-TYR--GLN-604; ALA-637;
RP   ARG-639; ARG-665 AND TRP-831.
RX   PubMed=29433126; DOI=10.1038/nature25478;
RA   Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T.,
RA   Kurinov I., Sicheri F., Therrien M.;
RT   "MEK drives BRAF activation through allosteric control of KSR proteins.";
RL   Nature 554:549-553(2018).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-227; ALA-359 AND HIS-663.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Part of a multiprotein signaling complex which promotes
CC       phosphorylation of Raf family members and activation of downstream MAP
CC       kinases (By similarity). Independently of its kinase activity, acts as
CC       MAP2K1/MEK1 and MAP2K2/MEK2-dependent allosteric activator of BRAF;
CC       upon binding to MAP2K1/MEK1 or MAP2K2/MEK2, dimerizes with BRAF and
CC       promotes BRAF-mediated phosphorylation of MAP2K1/MEK1 and/or
CC       MAP2K2/MEK2 (PubMed:29433126). Promotes activation of MAPK1 and/or
CC       MAPK3, both in response to EGF and to cAMP (By similarity). Its kinase
CC       activity is unsure (By similarity). Some protein kinase activity has
CC       been detected in vitro, however the physiological relevance of this
CC       activity is unknown (By similarity). {ECO:0000250|UniProtKB:Q61097,
CC       ECO:0000269|PubMed:29433126}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:Q61097};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:Q61097};
CC   -!- SUBUNIT: Homodimer (PubMed:29433126). Heterodimerizes (via N-terminus)
CC       with BRAF (via N-terminus) in a MAP2K1/MEK1 or MAP2K2/MEK2-dependent
CC       manner (PubMed:29433126). Interacts with MAP2K1/MEK1 and MAP2K2/MEK2
CC       (PubMed:10409742, PubMed:29433126). Binding to MAP2K1/MEK1 releases the
CC       intramolecular inhibitory interaction between KSR1 N-terminus and
CC       kinase domains which is required for the subsequent RSK1 dimerization
CC       with BRAF (PubMed:29433126). Identified in a complex with AKAP13,
CC       MAP2K1 and BRAF (By similarity). Interacts with AKAP13 and BRAF
CC       (PubMed:21102438). Interacts with RAF and MAPK/ERK, in a Ras-dependent
CC       manner (By similarity). Interacts with 14-3-3 proteins including YWHAB
CC       (By similarity). Interacts with HSP90AA1/HSP90, YWHAE/14-3-3 and CDC37
CC       (PubMed:10409742, PubMed:29433126). The binding of 14-3-3 proteins to
CC       phosphorylated KSR1 prevents the membrane localization (By similarity).
CC       Interacts with MARK3/C-TAK1 (PubMed:12941695). Interacts with PPP2R1A
CC       and PPP2CA (By similarity). Interacts with isoform 1 of VRK2
CC       (PubMed:20679487). {ECO:0000250|UniProtKB:Q61097,
CC       ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:12941695,
CC       ECO:0000269|PubMed:20679487, ECO:0000269|PubMed:21102438,
CC       ECO:0000269|PubMed:29433126}.
CC   -!- INTERACTION:
CC       Q8IVT5; P36507: MAP2K2; NbExp=9; IntAct=EBI-486984, EBI-1056930;
CC       Q8IVT5; Q86Y07: VRK2; NbExp=4; IntAct=EBI-486984, EBI-1207615;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20679487}. Membrane
CC       {ECO:0000269|PubMed:20679487}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:20679487}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q61097}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q61097}. Cell projection, ruffle membrane
CC       {ECO:0000250|UniProtKB:Q61097}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:20679487}. Note=In unstimulated cells, where the
CC       phosphorylated form is bound to a 14-3-3 protein, sequestration in the
CC       cytoplasm occurs. Following growth factor treatment, the protein is
CC       free for membrane translocation, and it moves from the cytoplasm to the
CC       cell periphery. {ECO:0000305|PubMed:12007434}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8IVT5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IVT5-2; Sequence=VSP_055656, VSP_055657;
CC       Name=3;
CC         IsoId=Q8IVT5-3; Sequence=VSP_055655;
CC       Name=4;
CC         IsoId=Q8IVT5-4; Sequence=VSP_055655, VSP_055657;
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive. The domain is sufficient for KSR1 and KSR1-mediated MAP2K1
CC       and MAP2K2 membrane localization. The domain is required but not
CC       sufficient for MAP kinase-mediated inhibition of ELK1 phosphorylation
CC       (PubMed:10409742). {ECO:0000255, ECO:0000269|PubMed:10409742}.
CC   -!- DOMAIN: The N-terminal region mediates interaction with BRAF
CC       (PubMed:29433126). Also mediates membrane localization (By similarity).
CC       {ECO:0000250|UniProtKB:Q61097, ECO:0000269|PubMed:29433126}.
CC   -!- PTM: Phosphorylated on Ser-311 and, to a higher extent, on Ser-406 by
CC       MARK3. Dephosphorylated on Ser-406 by PPP2CA. In resting cells,
CC       phosphorylated KSR1 is cytoplasmic and in stimulated cells,
CC       dephosphorylated KSR1 is membrane-associated. Phosphorylated by PKA at
CC       Ser-888. Phosphorylation at Ser-888 is required for cAMP-dependent
CC       activation of MAPK1 and/or MAPK3 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61097}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- CAUTION: Although it belongs to the protein kinase superfamily, the
CC       ATP-binding motif VAIK has an arginine instead of a lysine residue
CC       suggesting that KSR1 cannot bind ATP and therefore lacks protein kinase
CC       activity. However, KSR1 is capable of binding ATP (PubMed:29433126).
CC       Has protein kinase activity towards MAP2K1 in the presence of RAF1/c-
CC       RAF in vitro (By similarity). {ECO:0000250|UniProtKB:Q61097,
CC       ECO:0000269|PubMed:29433126, ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KSR1ID41107ch17q11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC069366; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC015688; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC042106; AAH42106.1; -; mRNA.
DR   EMBL; U43586; AAC50354.1; -; mRNA.
DR   CCDS; CCDS58532.1; -. [Q8IVT5-4]
DR   RefSeq; NP_055053.1; NM_014238.1. [Q8IVT5-4]
DR   RefSeq; XP_011523731.1; XM_011525429.2. [Q8IVT5-1]
DR   RefSeq; XP_016880760.1; XM_017025271.1. [Q8IVT5-3]
DR   RefSeq; XP_016880761.1; XM_017025272.1. [Q8IVT5-3]
DR   RefSeq; XP_016880762.1; XM_017025273.1. [Q8IVT5-3]
DR   RefSeq; XP_016880763.1; XM_017025274.1. [Q8IVT5-3]
DR   RefSeq; XP_016880764.1; XM_017025275.1. [Q8IVT5-3]
DR   RefSeq; XP_016880765.1; XM_017025276.1. [Q8IVT5-3]
DR   PDB; 5VYK; X-ray; 1.75 A; A/C=27-172.
DR   PDB; 7JUW; X-ray; 2.88 A; B=591-899.
DR   PDB; 7JUX; X-ray; 3.34 A; A=591-899.
DR   PDB; 7JUY; X-ray; 3.10 A; B=591-899.
DR   PDB; 7JUZ; X-ray; 3.21 A; A=591-899.
DR   PDB; 7JV0; X-ray; 3.63 A; A=591-899.
DR   PDB; 7JV1; X-ray; 3.62 A; D=591-899.
DR   PDBsum; 5VYK; -.
DR   PDBsum; 7JUW; -.
DR   PDBsum; 7JUX; -.
DR   PDBsum; 7JUY; -.
DR   PDBsum; 7JUZ; -.
DR   PDBsum; 7JV0; -.
DR   PDBsum; 7JV1; -.
DR   AlphaFoldDB; Q8IVT5; -.
DR   SMR; Q8IVT5; -.
DR   BioGRID; 114371; 122.
DR   CORUM; Q8IVT5; -.
DR   DIP; DIP-32619N; -.
DR   IntAct; Q8IVT5; 359.
DR   MINT; Q8IVT5; -.
DR   STRING; 9606.ENSP00000381958; -.
DR   BindingDB; Q8IVT5; -.
DR   ChEMBL; CHEMBL1938215; -.
DR   iPTMnet; Q8IVT5; -.
DR   PhosphoSitePlus; Q8IVT5; -.
DR   BioMuta; KSR1; -.
DR   DMDM; 56749095; -.
DR   EPD; Q8IVT5; -.
DR   jPOST; Q8IVT5; -.
DR   MassIVE; Q8IVT5; -.
DR   MaxQB; Q8IVT5; -.
DR   PaxDb; Q8IVT5; -.
DR   PeptideAtlas; Q8IVT5; -.
DR   PRIDE; Q8IVT5; -.
DR   ProteomicsDB; 31779; -.
DR   ProteomicsDB; 43732; -.
DR   ProteomicsDB; 70766; -. [Q8IVT5-1]
DR   ProteomicsDB; 70767; -. [Q8IVT5-2]
DR   ProteomicsDB; 70768; -. [Q8IVT5-3]
DR   Antibodypedia; 2110; 434 antibodies from 32 providers.
DR   DNASU; 8844; -.
DR   Ensembl; ENST00000398988.7; ENSP00000381958.3; ENSG00000141068.15. [Q8IVT5-4]
DR   Ensembl; ENST00000509603.6; ENSP00000438795.2; ENSG00000141068.15. [Q8IVT5-4]
DR   GeneID; 8844; -.
DR   KEGG; hsa:8844; -.
DR   UCSC; uc002gzo.2; human. [Q8IVT5-1]
DR   CTD; 8844; -.
DR   DisGeNET; 8844; -.
DR   GeneCards; KSR1; -.
DR   HGNC; HGNC:6465; KSR1.
DR   HPA; ENSG00000141068; Tissue enhanced (pancreas).
DR   MIM; 601132; gene.
DR   neXtProt; NX_Q8IVT5; -.
DR   OpenTargets; ENSG00000141068; -.
DR   PharmGKB; PA30254; -.
DR   VEuPathDB; HostDB:ENSG00000141068; -.
DR   eggNOG; KOG0193; Eukaryota.
DR   GeneTree; ENSGT00940000156066; -.
DR   InParanoid; Q8IVT5; -.
DR   OrthoDB; 281487at2759; -.
DR   PhylomeDB; Q8IVT5; -.
DR   TreeFam; TF317006; -.
DR   PathwayCommons; Q8IVT5; -.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; Q8IVT5; -.
DR   SIGNOR; Q8IVT5; -.
DR   BioGRID-ORCS; 8844; 16 hits in 1111 CRISPR screens.
DR   ChiTaRS; KSR1; human.
DR   GeneWiki; KSR1; -.
DR   GenomeRNAi; 8844; -.
DR   Pharos; Q8IVT5; Tbio.
DR   PRO; PR:Q8IVT5; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q8IVT5; protein.
DR   Bgee; ENSG00000141068; Expressed in body of pancreas and 169 other tissues.
DR   ExpressionAtlas; Q8IVT5; baseline and differential.
DR   Genevisible; Q8IVT5; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0071889; F:14-3-3 protein binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005078; F:MAP-kinase scaffold activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0019933; P:cAMP-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0043405; P:regulation of MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   CDD; cd00029; C1; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR025561; KSR_SAM-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF13543; SAM_KSR1; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cell projection; Cytoplasm; Endoplasmic reticulum; Kinase; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..923
FT                   /note="Kinase suppressor of Ras 1"
FT                   /id="PRO_0000086229"
FT   DOMAIN          613..883
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         347..391
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          1..172
FT                   /note="Mediates association with membranes"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   REGION          1..26
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          174..246
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          265..295
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          435..484
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          557..592
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        187..246
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        440..467
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        565..579
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        733
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         348
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         360
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         363
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         373
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         376
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         381
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         384
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         391
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   BINDING         619..627
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         735
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q6VAB6"
FT   BINDING         750
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q6VAB6"
FT   MOD_RES         270
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         274
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         351
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         406
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         425
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         569
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         888
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61097"
FT   VAR_SEQ         1..137
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055655"
FT   VAR_SEQ         504..526
FT                   /note="VPSAGHCWKCLLIAESLKENAFN -> D (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8521512"
FT                   /id="VSP_055656"
FT   VAR_SEQ         898..923
FT                   /note="DINSSKVVPRFERFGLGVLESSNPKM -> EL (in isoform 2 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8521512"
FT                   /id="VSP_055657"
FT   VARIANT         227
FT                   /note="S -> P"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040658"
FT   VARIANT         359
FT                   /note="V -> A"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046048"
FT   VARIANT         663
FT                   /note="Q -> H"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046049"
FT   MUTAGEN         47
FT                   /note="L->D: Reduces interaction with BRAF and MAP2K1 and
FT                   thus phosphorylation of MAP2K1."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         62
FT                   /note="C->D: Reduces interaction with BRAF and MAP2K1 and
FT                   thus phosphorylation of MAP2K1."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         72
FT                   /note="E->K: Loss of interaction with BRAF and MAP2K1 and
FT                   severe decrease in MAP2K1 phosphorylation levels."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         602..604
FT                   /note="YLQ->DDE: No effect on MAP2K1- or
FT                   MAP2K2-mediated-BRAF-KSR1 dimerization and BRAF
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         637
FT                   /note="A->F: No effect on MAP2K1 or MAP2K2
FT                   mediated-BRAF-KSR1 dimerization and BRAF activation."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         639
FT                   /note="R->M: No effect on MAP2K1 mediated-BRAF-KSR1
FT                   dimerization and BRAF activation."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         665
FT                   /note="R->H: Loss of MAP2K1 mediated-BRAF-KSR1
FT                   dimerization."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   MUTAGEN         831
FT                   /note="W->R: Loss of the interaction with MAP2K1 resulting
FT                   in loss of BRAF-KSR1 dimerization and BRAF activation. No
FT                   effect on ATP binding or interaction with HSP90AA1, 14-3-3
FT                   and CDC37."
FT                   /evidence="ECO:0000269|PubMed:29433126"
FT   CONFLICT        243..265
FT                   /note="FSEGLSDTCIPLHASGRLTPRAL -> EFRHTSALTQHTAHTQHTSAHTQ
FT                   (in Ref. 3; AAH42106)"
FT                   /evidence="ECO:0000305"
FT   HELIX           34..61
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           67..93
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           101..104
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           109..115
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           120..124
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           132..137
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           140..149
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           154..170
FT                   /evidence="ECO:0007829|PDB:5VYK"
FT   HELIX           603..605
FT                   /evidence="ECO:0007829|PDB:7JUX"
FT   STRAND          606..608
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          614..621
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          626..631
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          635..642
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           648..662
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          672..678
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          681..687
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          691..693
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           694..698
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           709..726
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           736..738
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          739..742
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          745..748
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           753..755
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   STRAND          767..770
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           773..777
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           781..786
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           793..795
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           800..816
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           826..834
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           837..845
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           850..859
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           864..866
FT                   /evidence="ECO:0007829|PDB:7JUW"
FT   HELIX           870..878
FT                   /evidence="ECO:0007829|PDB:7JUW"
SQ   SEQUENCE   923 AA;  102160 MW;  61BF0F1598349540 CRC64;
     MDRAALRAAA MGEKKEGGGG GDAAAAEGGA GAAASRALQQ CGQLQKLIDI SIGSLRGLRT
     KCAVSNDLTQ QEIRTLEAKL VRYICKQRQC KLSVAPGERT PELNSYPRFS DWLYTFNVRP
     EVVQEIPRDL TLDALLEMNE AKVKETLRRC GASGDECGRL QYALTCLRKV TGLGGEHKED
     SSWSSLDARR ESGSGPSTDT LSAASLPWPP GSSQLGRAGN SAQGPRSISV SALPASDSPT
     PSFSEGLSDT CIPLHASGRL TPRALHSFIT PPTTPQLRRH TKLKPPRTPP PPSRKVFQLL
     PSFPTLTRSK SHESQLGNRI DDVSSMRFDL SHGSPQMVRR DIGLSVTHRF STKSWLSQVC
     HVCQKSMIFG VKCKHCRLKC HNKCTKEAPA CRISFLPLTR LRRTESVPSD INNPVDRAAE
     PHFGTLPKAL TKKEHPPAMN HLDSSSNPSS TTSSTPSSPA PFPTSSNPSS ATTPPNPSPG
     QRDSRFNFPA AYFIHHRQQF IFPVPSAGHC WKCLLIAESL KENAFNISAF AHAAPLPEAA
     DGTRLDDQPK ADVLEAHEAE AEEPEAGKSE AEDDEDEVDD LPSSRRPWRG PISRKASQTS
     VYLQEWDIPF EQVELGEPIG QGRWGRVHRG RWHGEVAIRL LEMDGHNQDH LKLFKKEVMN
     YRQTRHENVV LFMGACMNPP HLAIITSFCK GRTLHSFVRD PKTSLDINKT RQIAQEIIKG
     MGYLHAKGIV HKDLKSKNVF YDNGKVVITD FGLFGISGVV REGRRENQLK LSHDWLCYLA
     PEIVREMTPG KDEDQLPFSK AADVYAFGTV WYELQARDWP LKNQAAEASI WQIGSGEGMK
     RVLTSVSLGK EVSEILSACW AFDLQERPSF SLLMDMLEKL PKLNRRLSHP GHFWKSADIN
     SSKVVPRFER FGLGVLESSN PKM
//
